- Granisetron is a proven, effective treatment option for the prevention of CINV, and its therapeutic benefits are well established2,5
- The unique polymer technology of SUSTOL is engineered to allow for a sustained and controlled release of granisetron to prevent CINV for ≥5 days1
- SUSTOL in engineered using a unique polymer technology that enables a controlled release of the otherwise shorter-acting granisetron1,2
- After subcutaneous injection, the polymer undergoes hydrolysis and delivers granisetron in a controlled, sustained release for ≥5 days1,2
- After the granisetron has been released, the polymer hydrolyzes and is eliminated from the body1,2
- SUSTOL is indicated for the prevention of CINV due to MEC and AC combination chemotherapy.
5-HT3 RA=5-hydroxytryptamine receptor antagonist; AC=anthracycline/cyclophosphamide; CINV=chemotherapy-induced nausea and vomiting. MEC=moderately emetogenic chemotherapy.
- SUSTOL [prescribing information]. Heron Therapeutics, Inc., 2017.
- Ottoboni et al. J Exp Pharmacol. 2014.
- Aloxi [prescribing information]. Helsinn Therapeutics (U.S.), Inc., 2020.
- Zofran [prescribing information]. GlaxoSmithKline. 2017.
- Kytril [prescribing information]. Genentech, Inc., 2011.
- Sancuso [prescribing information]. Kyowa Kirin, Inc., 2020.
- Anzemet [prescribing information]. Validus Pharmaceuticals LLC, 2016.
- Schnadig et al. Future Oncol. 2016.
- Zhou et al. Ther Clin Risk Manag. 2015.